KCPG
XERS icon

Kavar Capital Partners Group’s Xeris Biopharma Holdings XERS Stock Holding History

Kavar Capital Partners Group’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-17,000
Closed -$27.7K – 162
2023
Q1 		$27.7K Buy
+17,000
New +$21.3K 0.01% 161

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Kavar Capital Partners Group's XERS Position: Q2 2023 in Review

Kavar Capital Partners Group sold out of Xeris Biopharma Holdings (XERS) in Q2 2023, closing a stake of 17,000 shares — an estimated $27.7K sold.

Kavar Capital Partners Group first reported a position in XERS in Q1 2023 and held it in 1 quarter. The position peaked at $27.7K in Q1 2023. 103 funds tracked by Wall St. Rank hold XERS as of Q2 2023.

  • Kavar Capital Partners Group reported no remaining Xeris Biopharma Holdings position as of Q2 2023 after selling out during the quarter.
  • Kavar Capital Partners Group sold 17,000 Xeris Biopharma Holdings shares in Q2 2023, an estimated $27.7K.
  • Kavar Capital Partners Group first reported a position in Xeris Biopharma Holdings in Q1 2023 and held it in 1 quarter.
  • Kavar Capital Partners Group's Xeris Biopharma Holdings position peaked at $27.7K in Q1 2023.
  • 103 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2023.

Based on Kavar Capital Partners Group's 13F filing for Q2 2023, filed 7 Aug 2023.